Physician profile
Michael E Mendelsohn
NPI 1851435549
$1,552,546.91
in general payments reported to CMS, 2019-2025
3 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $437K · 2020: $456K · 2021: $268K · 2022: $135K · 2023: $196K · 2024: $60K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $255K · Travel and Lodging: $893 · Food and Beverage: $17.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $255,000.00 |
| Travel and Lodging | $893.49 |
| Food and Beverage | $17.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $1,521,209.86 | 2019-2024 | |
| Ironwood Pharmaceuticals, INC | $31,315.00 | 2019 | |
| Takeda Pharmaceutical Company, Limited | $22.05 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mendelsohn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.